Literature DB >> 24335759

Actual developments in European regulatory and health technology assessment of new cancer drugs: what does this mean for oncology in Europe?

L Bergmann1, H Enzmann, K Broich, A Hebborn, S Marsoni, L Goh, J F Smyth, H Zwierzina.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24335759     DOI： 10.1093/annonc/mdt488

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  4 in total

1.  Bridging the gap: Can International Consortium of Health Outcomes Measurement standard sets align outcomes accepted for regulatory and health technology assessment decision-making of oncology medicines.

Authors:  Rachel R J Kalf; Rick A Vreman; Diana M J Delnoij; Marcel L Bouvy; Wim G Goettsch
Journal:  Pharmacol Res Perspect       Date:  2021-04

2.  Solving the Evidence Interpretability Crisis in Health Technology Assessment: A Role for Mechanistic Models?

Authors:  Eulalie Courcelles; Jean-Pierre Boissel; Jacques Massol; Ingrid Klingmann; Riad Kahoul; Marc Hommel; Emmanuel Pham; Alexander Kulesza
Journal:  Front Med Technol       Date:  2022-02-24

3.  Impact of Managed Entry Agreements on availability of and timely access to medicines: an ex-post evaluation of agreements implemented for oncology therapies in four countries.

Authors:  Olina Efthymiadou; Panos Kanavos
Journal:  BMC Health Serv Res       Date:  2022-08-20       Impact factor: 2.908

4.  Access to innovative oncology medicines in Europe.

Authors:  L Bergmann; H Enzmann; S Thirstrup; J K Schweim; I Widera; H Zwierzina
Journal:  Ann Oncol       Date:  2015-11-16       Impact factor: 32.976
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.